ResearcherNational Cancer Center HospitalNo recent work listed
Yoko Shimada
Matched on OpenAlex author ID A5108549235. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2017: 2 papers
Papers 2
- Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic … Co-author DOI 10.1097/mpa.0000000000000760↗
- An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2016-0194↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kazuaki Shimada · 2 shared papers, 2017 · strength 0.12
- Paper An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. DOI 10.1634/theoncologist.2016-0194↗
- Paper Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay a… DOI 10.1097/mpa.0000000000000760↗
- Hideyuki Hayashi · 2 shared papers, 2017 · strength 0.12
- Paper An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. DOI 10.1634/theoncologist.2016-0194↗
- Paper Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay a… DOI 10.1097/mpa.0000000000000760↗
- Hideki Ueno · 2 shared papers, 2017 · strength 0.12
- Paper An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. DOI 10.1634/theoncologist.2016-0194↗
- Paper Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay a… DOI 10.1097/mpa.0000000000000760↗
- Takuji Okusaka · 2 shared papers, 2017 · strength 0.12
- Paper An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. DOI 10.1634/theoncologist.2016-0194↗
- Paper Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay a… DOI 10.1097/mpa.0000000000000760↗
- Nobuyoshi Hiraoka · 2 shared papers, 2017 · strength 0.12
- Paper An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. DOI 10.1634/theoncologist.2016-0194↗
- Paper Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay a… DOI 10.1097/mpa.0000000000000760↗
- Chigusa Morizane · 2 shared papers, 2017 · strength 0.12
- Paper An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. DOI 10.1634/theoncologist.2016-0194↗
- Paper Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay a… DOI 10.1097/mpa.0000000000000760↗
- Yoshinori Ino · 1 shared paper, 2017 · strength 0.06
- Yoshito Komatsu · 1 shared paper, 2017 · strength 0.06
- Naoya Sakamoto · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.